This raises the question regarding the significance of mutations in the ARID1A gene as an earlier biomarker in endometriosis patients to tackle ovarian cancer initiation, as partial loss of BAF250a expression has been found in lesions of patients with endometriosis [7]. This evidence concerns the gene ARID1A and endometriosis.